246 related articles for article (PubMed ID: 12394347)
1. A population-based study of Ashkenazi Jewish women's attitudes toward genetic discrimination and BRCA1/2 testing.
Lehmann LS; Weeks JC; Klar N; Garber JE
Genet Med; 2002; 4(5):346-52. PubMed ID: 12394347
[TBL] [Abstract][Full Text] [Related]
2. Perceptions of Ashkenazi Jewish breast cancer patients on genetic testing for mutations in BRCA1 and BRCA2.
Phillips KA; Warner E; Meschino WS; Hunter J; Abdolell M; Glendon G; Andrulis IL; Goodwin PJ
Clin Genet; 2000 May; 57(5):376-83. PubMed ID: 10852372
[TBL] [Abstract][Full Text] [Related]
3. Cancer genetics knowledge and beliefs and receipt of results in Ashkenazi Jewish individuals receiving counseling for BRCA1/2 mutations.
Kelly K; Leventhal H; Marvin M; Toppmeyer D; Baran J; Schwalb M
Cancer Control; 2004; 11(4):236-44. PubMed ID: 15284715
[TBL] [Abstract][Full Text] [Related]
4. Attitude towards and factors affecting uptake of population-based BRCA testing in the Ashkenazi Jewish population: a cohort study.
Manchanda R; Burnell M; Gaba F; Sanderson S; Loggenberg K; Gessler S; Wardle J; Side L; Desai R; Brady AF; Dorkins H; Wallis Y; Chapman C; Jacobs C; Tomlinson I; Beller U; Menon U; Jacobs I
BJOG; 2019 May; 126(6):784-794. PubMed ID: 30767407
[TBL] [Abstract][Full Text] [Related]
5. Impact of educational print materials on knowledge, attitudes, and interest in BRCA1/BRCA2: testing among Ashkenazi Jewish women.
Schwartz MD; Benkendorf J; Lerman C; Isaacs C; Ryan-Robertson A; Johnson L
Cancer; 2001 Aug; 92(4):932-40. PubMed ID: 11550168
[TBL] [Abstract][Full Text] [Related]
6. Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers.
Finkelman BS; Rubinstein WS; Friedman S; Friebel TM; Dubitsky S; Schonberger NS; Shoretz R; Singer CF; Blum JL; Tung N; Olopade OI; Weitzel JN; Lynch HT; Snyder C; Garber JE; Schildkraut J; Daly MB; Isaacs C; Pichert G; Neuhausen SL; Couch FJ; van't Veer L; Eeles R; Bancroft E; Evans DG; Ganz PA; Tomlinson GE; Narod SA; Matloff E; Domchek S; Rebbeck TR
J Clin Oncol; 2012 Apr; 30(12):1321-8. PubMed ID: 22430266
[TBL] [Abstract][Full Text] [Related]
7. Clinicians' attitudes toward general screening of the Ashkenazi-Jewish population for prevalent founder BRCA1/2 and LRRK2 mutations.
Shkedi-Rafid S; Ofer-Bialer G; Meiner V; Calderon-Margalit R
Public Health Genomics; 2013; 16(4):174-83. PubMed ID: 23816973
[TBL] [Abstract][Full Text] [Related]
8. The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families.
Palma MD; Domchek SM; Stopfer J; Erlichman J; Siegfried JD; Tigges-Cardwell J; Mason BA; Rebbeck TR; Nathanson KL
Cancer Res; 2008 Sep; 68(17):7006-14. PubMed ID: 18703817
[TBL] [Abstract][Full Text] [Related]
9. Concomitant BRCA1 and BRCA2 gene mutations in an Ashkenazi Jewish woman with primary breast and ovarian cancer.
Spannuth WA; Thaker PH; Sood AK
Am J Obstet Gynecol; 2007 Apr; 196(4):e6-9. PubMed ID: 17403394
[TBL] [Abstract][Full Text] [Related]
10. Who's to blame? Accounts of genetic responsibility and blame among Ashkenazi Jewish women at risk of BRCA breast cancer.
Mozersky J
Sociol Health Illn; 2012 Jun; 34(5):776-90. PubMed ID: 22257279
[TBL] [Abstract][Full Text] [Related]
11. Community attitudes towards a Jewish community BRCA1/2 testing program.
Cousens N; Kaur R; Meiser B; Andrews L
Fam Cancer; 2017 Jan; 16(1):17-28. PubMed ID: 27480161
[TBL] [Abstract][Full Text] [Related]
12. Hereditary breast/ovarian cancer--pitfalls in genetic counseling.
Dagan E; Gershoni-Baruch R
Clin Genet; 2001 Oct; 60(4):310-3. PubMed ID: 11683778
[TBL] [Abstract][Full Text] [Related]
13. Coinheritance of BRCA1 and BRCA2 mutations with Fanconi anemia and Bloom syndrome mutations in Ashkenazi Jewish population: possible role in risk modification for cancer development.
Koren-Michowitz M; Friedman E; Gershoni-Baruch R; Brok-Simoni F; Patael Y; Rechavi G; Amariglio N
Am J Hematol; 2005 Mar; 78(3):203-6. PubMed ID: 15726604
[TBL] [Abstract][Full Text] [Related]
14. Patients' attitudes about autonomy and confidentiality in genetic testing for breast-ovarian cancer susceptibility.
Benkendorf JL; Reutenauer JE; Hughes CA; Eads N; Willison J; Powers M; Lerman C
Am J Med Genet; 1997 Dec; 73(3):296-303. PubMed ID: 9415688
[TBL] [Abstract][Full Text] [Related]
15. Psychological impact of genetic testing for breast cancer susceptibility in women of Ashkenazi Jewish background: a prospective study.
Andrews L; Meiser B; Apicella C; Tucker K
Genet Test; 2004; 8(3):240-7. PubMed ID: 15727246
[TBL] [Abstract][Full Text] [Related]
16. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer.
Moslehi R; Chu W; Karlan B; Fishman D; Risch H; Fields A; Smotkin D; Ben-David Y; Rosenblatt J; Russo D; Schwartz P; Tung N; Warner E; Rosen B; Friedman J; Brunet JS; Narod SA
Am J Hum Genet; 2000 Apr; 66(4):1259-72. PubMed ID: 10739756
[TBL] [Abstract][Full Text] [Related]
17. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
18. Population-Based Study of Attitudes toward BRCA Genetic Testing among Orthodox Jewish Women.
Tang EY; Trivedi MS; Kukafka R; Chung WK; David R; Respler L; Leifer S; Schechter I; Crew KD
Breast J; 2017 May; 23(3):333-337. PubMed ID: 27900810
[TBL] [Abstract][Full Text] [Related]
19. Hereditary breast cancer in Jews.
Rubinstein WS
Fam Cancer; 2004; 3(3-4):249-57. PubMed ID: 15516849
[TBL] [Abstract][Full Text] [Related]
20. Attitudes, knowledge, risk perceptions and decision-making among women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2 and their spouses.
Bluman LG; Rimer BK; Regan Sterba K; Lancaster J; Clark S; Borstelmann N; Iglehart JD; Winer EP
Psychooncology; 2003; 12(5):410-27. PubMed ID: 12833555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
